By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous metabolic agents > Mitapivat > Mitapivat Dosage
Miscellaneous metabolic agents
https://themeditary.com/dosage-information/mitapivat-dosage-10420.html

Mitapivat Dosage

Drug Detail:Mitapivat (Mitapivat [ mye-ta-piv-at ])

Drug Class: Miscellaneous metabolic agents

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Hemolytic Anemia

Initial dose: 5 mg orally twice a day
Maintenance dose: 5 to 50 mg orally twice a day

Dose Titration Schedule:

  • Week 1 through 4: 5 mg orally twice a day
  • Week 5 through 8:
  • If hemoglobin is below normal range or a transfusion was required within the last 8 weeks: Dosage should be increased to 20 mg orally twice a day and maintained for 4 weeks.
  • If hemoglobin is with normal range and a transfusion has not been required within the last 8 weeks: Dosage should be maintained at 5 mg orally twice a day.
  • Week 9 through 12:
  • If hemoglobin is below normal range or a transfusion was required within the last 8 weeks: Dosage should be increased to 50 mg orally twice a day and maintained thereafter.
  • If hemoglobin is with normal range and a transfusion has not been required within the last 8 weeks: Current dosage should be maintained (5 mg orally twice a day or 20 mg orally twice a day).
  • Maintenance: If hemoglobin decreases, up-titration to the maximum of 50 mg orally twice a day (as per the specified schedule) should be considered.

Dose Taper Schedule:
  • If current dose is 5 mg orally twice a day:
  • Day 1 through 7: 5 mg orally once a day
  • Day 8: This drug should be discontinued.
  • If current dose is 20 mg orally twice a day:
  • Day 1 through 7: 20 mg orally once a day
  • Day 8 through 14: 5 mg orally once a day
  • Day 15: This drug should be discontinued.
  • If current dose is 50 mg orally twice a day:
  • Day 1 through 7: 50 mg orally once a day
  • Day 8 through 14: 20 mg orally once a day
  • Day 15: This drug should be discontinued.

Comments:
  • To gradually increase hemoglobin, this drug should be titrated from 5 mg twice a day to 20 mg twice a day, and then to the maximum recommended dose of 50 mg twice a day; these dose increases should occur every 4 weeks.
  • Hemoglobin and transfusion requirement should be assessed before increasing to the next dose level; some patients may reach and maintain normal hemoglobin at 5 mg twice a day or 20 mg twice a day.
  • This drug should be discontinued if no benefit has been observed by 24 weeks (based on hemoglobin and hemolysis laboratory results and transfusion requirements).
  • To reduce the risk of acute hemolysis, abrupt interruption/discontinuation should be avoided when possible; the dose should be tapered to gradually discontinue the drug. Patients should be monitored for signs of acute hemolysis and worsening of anemia.

Use: For the treatment of hemolytic anemia in patients with pyruvate kinase deficiency

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Moderate or severe liver dysfunction: Not recommended.

Dose Adjustments

For Adverse Reactions and Hemoglobin Levels Above Normal:

  • If dose reduction is needed due to an adverse reaction or tolerability, or for hemoglobin above normal, the dose may be reduced to the next lower dose level (20 mg orally twice a day or 5 mg orally twice a day).
  • If a patient needs to discontinue this drug, the dose taper schedule should be followed.
  • In situations where the risk to the patient due to the adverse reaction or hemoglobin above normal is greater than the risk of acute hemolysis due to sudden withdrawal of the drug, this drug may be stopped without taper and patients should be monitored for signs of acute hemolysis.

For Drug Interactions:
  • Strong CYP450 3A inhibitors: Coadministration should be avoided.
  • Moderate CYP450 3A inhibitors: Monitoring of hemoglobin and for increased risks of adverse reactions from this drug is recommended; when coadministered, this drug should not be titrated beyond 20 mg orally twice a day.
  • Strong CYP450 3A inducers: Coadministration should be avoided.
  • Moderate CYP450 3A inducers: Alternative therapies should be considered during treatment with this drug; if there are no alternative therapies, hemoglobin should be monitored and the dose should be titrated beyond 50 mg orally twice a day, if necessary, but a maximum recommended dose of 100 mg orally twice a day should not be exceeded.

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Administer with or without food.
  • Swallow whole; do not split, crush, chew, or dissolve the tablets.

Storage requirements:
  • Store at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F).
  • Store the blister wallets in original carton until use.

Monitoring:
  • General: For increased risks of adverse reactions from this drug (during coadministration with moderate CYP450 inhibitors)
  • Hematologic: For signs of acute hemolysis and anemia (when discontinuing therapy); hemoglobin (during coadministration with moderate CYP450 inhibitors or inducers)

Patient advice:
  • Read the US FDA-approved patient labeling (Patient Information).
  • If a dose is missed by 4 hours or less, take it as soon as possible; if a dose is missed by more than 4 hours, do not take a replacement dose, and wait until the next scheduled dose. Subsequently, return to the normal dosing schedule.
  • Follow health care provider's instructions for discontinuing this drug; upon discontinuation, immediately report any symptoms suggestive of acute hemolysis (including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, shortness of breath) to health care provider for further evaluation.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by